Indinavir Sulfate
FDA-approved product (capsule, oral), marketed as Crixivan.
- Registered studies
- 50+
- Lab records
- 0
- Pathogens at ≥40%
- 3 of 4
Chemical structure
Existing / approved use
Documented · FDA, WHO, ChEMBLApproved for
- HIV infection
Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗
- WHO therapeutic group
- Protease inhibitors
- Anti-infective classification
- Classified as another kind of anti-infective (for example an antifungal, antiviral or antiparasitic medicine).WHO ATC J05AE02
Repurposing investigation
This medicine is being investigated here for AI-predicted antimicrobial activity against E. coli, MRSA and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.
AI-predicted activity
AI prediction · nothing measured- MRSA46.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- E. coli52.7% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- K. pneumoniae36.2% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- M. tuberculosis55.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.
Evidence
Clinical and experimental
Documented evidenceClinical
50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.
Experimental
No evidence found
No laboratory measurement against the four pathogens in the ChEMBL records loaded here.
Docking
Computational · nothing measuredDihydrofolate reductase ↗ (E. coli)
Not yet docked: queued in the docking rundetails
KPC-2 carbapenemase ↗ (K. pneumoniae)
Not yet docked: queued in the docking rundetails
Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)
Not yet docked: queued in the docking rundetails
Dihydrofolate reductase ↗ (MRSA)
Not yet docked: queued in the docking rundetails
AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.
Other medicines to investigate
AI prediction · nothing measuredOther repurposing candidates: approved medicines besides Indinavir Sulfate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.
Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.
- Nafarelin AcetateExisting use: Endometriosis58.6% AI-predicted activityagainst E. coli12 registered studies
- Goserelin AcetateExisting use: Breast cancer, Breast carcinoma, Carcinoma and 1 more58.5% AI-predicted activityagainst E. coli50+ registered studies
- Doxazosin MesylateExisting use: Benign prostatic hyperplasia, Hypertension, Myocardial infarction58.3% AI-predicted activityagainst E. coli50+ registered studies
- Chlorhexidine GluconateExisting use: Eye infection, Gingivitis, Infection and 2 more58.1% AI-predicted activityagainst E. coliLab records exist50+ registered studies
- Zavegepant HydrochlorideExisting use: Migraine disorder57.8% AI-predicted activityagainst E. coliNo documented evidence found
- Bremelanotide AcetateExisting use: Mental or behavioural disorder, Physiological sexual disorder, Sexual dysfunction57.4% AI-predicted activityagainst E. coli1 registered study
- Trametinib Dimethyl SulfoxideExisting use: Cancer, Cutaneous melanoma, Glioblastoma multiforme and 5 more57.2% AI-predicted activityagainst E. coli16 registered studies
- Degarelix AcetateExisting use: Prostate adenocarcinoma, Prostate cancer, Prostate carcinoma57.2% AI-predicted activityagainst E. coli50+ registered studies
- Cisapride MonohydrateExisting use: Gastrointestinal disease56.3% AI-predicted activityagainst E. coli5 registered studies
- Prazosin HydrochlorideExisting use: Diabetes mellitus, Hypertension56.3% AI-predicted activityagainst E. coli50+ registered studies
- PemigatinibExisting use: Cancer, Cholangiocarcinoma, Neoplasm56.0% AI-predicted activityagainst E. coli50+ registered studies
- AtogepantExisting use: Migraine disorder56.0% AI-predicted activityagainst E. coli36 registered studies
Registered studies
A registration describes a study; it does not establish a positive result.
A Study to Evaluate the Long-Term Effectiveness of Three Anti-HIV Drug Regimens in HIV Infected Patients Who Have Never Been Exposed to Highly Active Antiretroviral Therapy (HAART)
NCT00000922
Registered record
- Registry ID
- NCT00000922
- Conditions
- HIV Infections
- Interventions
- Indinavir sulfate; Abacavir sulfate; Nelfinavir mesylate; Efavirenz; Nevirapine; Lamivudine; Stavudine; Didanosine
- Study type
- INTERVENTIONAL
- Phase
- Not applicable
- Registry status
- Completed
- Start
- Not recorded
- Completion
- 2006-06
- Enrolment
- 1,710
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHIV InfectionsInterventionIndinavir sulfate; Abacavir sulfate; Nelfinavir mesylate; Efavirenz +4 morePhaseNot applicableRegistry statusCompletedTreatment With Interleukin-2 (IL-2) Plus Combination Anti-HIV-Drug Therapy (HAART) for Patients Formerly in ACTG 328
NCT00000923
Registered record
- Registry ID
- NCT00000923
- Conditions
- HIV Infections
- Interventions
- Indinavir sulfate; Lamivudine; Stavudine; Zidovudine; Didanosine; Aldesleukin
- Study type
- INTERVENTIONAL
- Phase
- Not applicable
- Registry status
- Completed
- Start
- Not recorded
- Completion
- 2004-08
- Enrolment
- 110
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHIV InfectionsInterventionIndinavir sulfate; Lamivudine; Stavudine; Zidovudine +2 morePhaseNot applicableRegistry statusCompletedA Study of Three Treatment Combinations Using Zidovudine Plus Lamivudine Plus Indinavir in HIV-Infected Patients
NCT00001084
Registered record
- Registry ID
- NCT00001084
- Conditions
- HIV Infections
- Interventions
- Indinavir sulfate; Lamivudine; Stavudine; Zidovudine
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Completed
- Start
- Not recorded
- Completion
- 1997-12
- Enrolment
- 500
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHIV InfectionsInterventionIndinavir sulfate; Lamivudine; Stavudine; ZidovudinePhasePhase 2Registry statusCompletedA Study of Three Anti-HIV Drug Combinations in Patients Who Have Taken Amprenavir
NCT00001095
Registered record
- Registry ID
- NCT00001095
- Conditions
- HIV Infections
- Interventions
- Indinavir sulfate; Amprenavir; Nevirapine; Lamivudine; Stavudine; Zidovudine
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Completed
- Start
- Not recorded
- Completion
- 1999-10
- Enrolment
- 94
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHIV InfectionsInterventionIndinavir sulfate; Amprenavir; Nevirapine; Lamivudine +2 morePhasePhase 2Registry statusCompletedSafety and Tolerance of Indinavir Plus Ritonavir in HIV-Positive Patients Failing Therapy With Amprenavir, Nelfinavir, or Saquinavir
NCT00001133
Registered record
- Registry ID
- NCT00001133
- Conditions
- HIV Infections
- Interventions
- Indinavir sulfate; Ritonavir
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Completed
- Start
- Not recorded
- Completion
- 2006-08
- Enrolment
- 50
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHIV InfectionsInterventionIndinavir sulfate; RitonavirPhasePhase 1Registry statusCompletedA Comparison of Two Anti-HIV Triple-Drug Combinations in HIV-Infected Patients
NCT00002168
Registered record
- Registry ID
- NCT00002168
- Conditions
- HIV Infections
- Interventions
- Indinavir sulfate; Lamivudine; Stavudine; Zidovudine; Didanosine
- Study type
- INTERVENTIONAL
- Phase
- Not applicable
- Registry status
- Completed
- Start
- Not recorded
- Completion
- Not recorded
- Enrolment
- 200
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHIV InfectionsInterventionIndinavir sulfate; Lamivudine; Stavudine; Zidovudine +1 morePhaseNot applicableRegistry statusCompletedIndinavir Plus Efavirenz Plus Adefovir Dipivoxil in HIV-Infected Patients Who Have Not Had Success With Nelfinavir
NCT00002220
Registered record
- Registry ID
- NCT00002220
- Conditions
- HIV Infections
- Interventions
- Indinavir sulfate; Efavirenz; Levocarnitine; Adefovir dipivoxil
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- Not recorded
- Completion
- Not recorded
- Enrolment
- 120
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHIV InfectionsInterventionIndinavir sulfate; Efavirenz; Levocarnitine; Adefovir dipivoxilPhasePhase 3Registry statusCompletedA Study of Indinavir Sulfate Given Together With Stavudine to HIV-Positive Patients
NCT00002354
Registered record
- Registry ID
- NCT00002354
- Conditions
- HIV Infections
- Interventions
- Indinavir sulfate; Stavudine
- Study type
- INTERVENTIONAL
- Phase
- Not applicable
- Registry status
- Completed
- Start
- Not recorded
- Completion
- Not recorded
- Enrolment
- 540
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHIV InfectionsInterventionIndinavir sulfate; StavudinePhaseNot applicableRegistry statusCompletedSafety and Effectiveness of an Anti-HIV Drug Combination in HIV-Positive Patients Who Have Failed Previous Treatment With Protease Inhibitors
NCT00002361
Registered record
- Registry ID
- NCT00002361
- Conditions
- HIV Infections
- Interventions
- Indinavir sulfate; Ritonavir
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Completed
- Start
- Not recorded
- Completion
- Not recorded
- Enrolment
- 30
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHIV InfectionsInterventionIndinavir sulfate; RitonavirPhasePhase 2Registry statusCompletedA Study of 141W94 in Combination With Other Anti-HIV Drugs
NCT00002372
Registered record
- Registry ID
- NCT00002372
- Conditions
- HIV Infections
- Interventions
- Indinavir sulfate; Amprenavir; Nelfinavir mesylate; Saquinavir
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Completed
- Start
- Not recorded
- Completion
- Not recorded
- Enrolment
- 48
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHIV InfectionsInterventionIndinavir sulfate; Amprenavir; Nelfinavir mesylate; SaquinavirPhasePhase 1Registry statusCompletedSafety and Effectiveness of Giving Indinavir and Nelfinavir to HIV-Infected Patients
NCT00002375
Registered record
- Registry ID
- NCT00002375
- Conditions
- HIV Infections
- Interventions
- Indinavir sulfate; Nelfinavir mesylate
- Study type
- INTERVENTIONAL
- Phase
- Not applicable
- Registry status
- Completed
- Start
- Not recorded
- Completion
- Not recorded
- Enrolment
- 24
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHIV InfectionsInterventionIndinavir sulfate; Nelfinavir mesylatePhaseNot applicableRegistry statusCompletedEffect of Indinavir Plus Two Other Anti-HIV Drugs on Blood Clotting in HIV-Positive Males With Hemophilia
NCT00002386
Registered record
- Registry ID
- NCT00002386
- Conditions
- HIV Infections; Hemophilia A
- Interventions
- Indinavir sulfate; Lamivudine; Stavudine; Zidovudine; Zalcitabine; Didanosine
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Completed
- Start
- Not recorded
- Completion
- Not recorded
- Enrolment
- 55
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHIV Infections; Hemophilia AInterventionIndinavir sulfate; Lamivudine; Stavudine; Zidovudine +2 morePhasePhase 4Registry statusCompletedA Study of Indinavir Taken With or Without DMP 266
NCT00002393
Registered record
- Registry ID
- NCT00002393
- Conditions
- HIV Infections
- Interventions
- Indinavir sulfate; Efavirenz
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- Not recorded
- Completion
- Not recorded
- Enrolment
- 300
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHIV InfectionsInterventionIndinavir sulfate; EfavirenzPhasePhase 3Registry statusCompletedA Study of Delavirdine Used Together With Other Anti-HIV Drugs in HIV-Infected Patients
NCT00002401
Registered record
- Registry ID
- NCT00002401
- Conditions
- HIV Infections
- Interventions
- Indinavir sulfate; Delavirdine mesylate; Lamivudine; Zidovudine
- Study type
- INTERVENTIONAL
- Phase
- Not applicable
- Registry status
- Completed
- Start
- Not recorded
- Completion
- Not recorded
- Enrolment
- 160
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHIV InfectionsInterventionIndinavir sulfate; Delavirdine mesylate; Lamivudine; ZidovudinePhaseNot applicableRegistry statusCompletedA Comparison of Two Dose Levels of Indinavir Combined With Two Nucleoside Analogue Reverse Transcriptase Inhibitors (NRTIs) in HIV-Infected Patients
NCT00002406
Registered record
- Registry ID
- NCT00002406
- Conditions
- HIV Infections
- Interventions
- Indinavir sulfate
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- Not recorded
- Completion
- Not recorded
- Enrolment
- 350
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHIV InfectionsInterventionIndinavir sulfatePhasePhase 3Registry statusCompleted